Hermes integrates Centiloid scale in latest software

Hermes Medical Solutions has secured U.S. Food and Drug Administration (FDA) clearance for the latest version of its flagship nuclear medicine imaging and dosimetry software, Hermia. 

A major highlight of the latest version is the integration of the Centiloid scale, a standardized method for quantifying amyloid PET imaging results, the company said. The update now allows clinicians to do the following: 

• Interpret amyloid PET results across different tracers and protocols using a unified standard.

• Enhance patient selection and treatment monitoring through improved comparability of quantitative imaging.

• Optimize FDG-PET brain scan analysis with on-the-fly normalization method changes, supported by side-by-side 3D visualizations of deviation images.

• Simultaneously display regions of both hyper- and hypometabolism in FDG-PET brain scans.

• Analyze novel 3D digital SPECT/CT images with extended visualization and comparison capabilities.

In addition to the Centiloid scale integration, Hermia now supports loading CT-based anatomical regions for organ dosimetry. Users can integrate external segmentation software with automatic region delineation and alignment, which further streamlines the dosimetry workflow, Hermes said.